PepGen, a Phase 1 biotech developing oligonucleotide therapies for neuromuscular diseases, filed on Friday with the SEC to raise up to $115 million in an initial public offering.
PepGen is generating a pipeline of oligonucleotide therapeutic candidates for the treatment of severe neuromuscular and neurologic diseases using its Enhanced Delivery Oligonucleotide (EDO) platform, which was initially developed through a collaboration between researchers at the University of Oxford and the Medical Research Council of United Kingdom Research and Innovation. Its lead candidate, PGN-EDO51, is being developed for Duchenne muscular dystrophy (DMD) and recently entered a Phase 1 trial in healthy normal volunteers, with topline data anticipated by the end of 2022.
The Cambridge, MA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol PEPG. PepGen filed confidentially on October 1, 2021. BofA Securities, SVB Leerink, Stifel, and Wedbush Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.